At a glance
ClinicalIndex Comparison RecordN/ACompleted· 76 enrolled
Drug / intervention
Freestyle Navigatordevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Continuous Glucose Monitoring With a Subcutaneous Sensor During Critical Illness and Surgery
In Brief
A clinical study evaluating Freestyle Navigator for Critical Illness. Completed, enrolled 76 participants across 1 site.
Detailed Summary
We hypothesize that measurements of interstitial fluid (ISF) glucose by the FreeStyle Navigator (Abbot Diabetes Care), a continuous glucose monitoring system, will correlate with blood glucose (BG) values in surgical and ICU patients with a clinically useful degree of accuracy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCritical Illness
CountriesUnited States
CollaboratorsAbbott Diabetes Care
Timeline
N/ACompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2008
First PostedJun 2008
Primary CompletionDec 2010
Study CompletionDec 2017
TodayJul 2026
First PostedJun 10, 2008
Enrollment StartJun 1, 2008
Primary CompletionDec 1, 2010
Study CompletionDec 1, 2017
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 18.1 years ago
Interventions
Freestyle Navigatordevice
Continuous glucose monitoring with the Freestyle Navigator for 72 hours or until discharge from the ICU